Genentech has launched an employee retention program aimed at retaining employees following the recent bid by Roche to acquire Genentech.
The Mercury News reported that Genentech’s plan is to spend $371 million in cash on retaining its personnel, which the company had planned to spend instead on its employees in a previously established stock option program. The prevailing wisdom is that spending the money now on cash will be much more attractive than spending the money on stock options to be cashed out in the future.
Will this program help to discourage the departures of personnel who would otherwise choose to leave the company, in light of the uncertainty now about its future?
In all likelihood, the answer to this question is “no.” Given the current state of the economy and the collapse of the housing market, the average Genentech employee will probably be concerned enough about his or her future to start looking for a new salaried position. Also, many of Genentech’s employees are already well enough off as a result of the company’s successes over the years to not be swayed by a retention package. Moreover, the conventional wisdom is that Roche will ultimately be successful in its bid to acquire Genentech, which means that many employee jobs may prove to be on the cutting block wiithin the very near future.
Still, you have to admire Genentech’s attempts to slow down the flow of departing employees out the company doors. I feel confident that most observers would agree that spending $371 million on retaining employees in the face of a likely acquisition is an impressive effort to ensure that the company can continue to operate, regardless of what happens with the acquisition effort. And, of course, such an effort may have the other important effect of maintaining the company’s value as the acquisition talks move forward. The California Biotech Blog will continue to watch this issue as it unfolds and will report on whether or not these efforts by Genentech prove to be successful.
2,081 total views, 1 views today